SAB Biotherapeutics, Inc.

SAB Biotherapeutics, Inc. (Nasdaq: SABS) is a clinical-stage biopharmaceutical company focused on developing human polyclonal antibody therapeutics using genetically engineered cattle. The company went public through a merger with Big Rock Partners Acquisition Corp, a SPAC sponsored by Big Rock Partners LLC that completed its IPO in 2020. The August 9, 2021 Form 10-Q filing, carrying accession number 0001493152-21-019063, was submitted during the pre-close period ahead of the business combination, which was ultimately completed in October 2021. The company operates in the biotechnology and clinical-stage therapeutics sector. For full filing history, deal timelines, and sponsor data on SABS and hundreds of other SPAC transactions, sign up for complete access at SpacDesk.